Study [mnob]
effects [qlco]
Dydrogesterone [horm, phsu, strd]
therapy [ftcn]
Serum [bdsu]
Lipoproteins [aapp, bacs]
Lp(a) [aapp, bacs]
postmenopausal [tmco]
Women [popg]
Additional [ftcn]
Unfavorable [qlco]
effects [qlco]
Dydrogesterone [horm, phsu, strd]
Introduction [hlca]
Hormone Replacement Therapy, Post-Menopausal [topp]
To [qlco]
Risk [qlco]
Cardiovascular disease [dsyn]
Attribute [idcn]
Part [spco]
effects [qlco]
Oestrogens [horm, phsu, strd]
Serum [bdsu]
Lipoproteins [aapp, bacs]
Little NOS [cgab, dsyn]
Known [qlco]
Possible [qlco]
Effect [qlco]
Progestagen [horm, phsu, strd]
Hormone replacement therapy [topp]
regimens [inpr]
Objective [inpr]
To [qlco]
Study [mnob]
Possible [qlco]
Serum lipids NOS [lbpr]
Lipoproteins [aapp, bacs]
Apolipoproteins [aapp, bacs]
Hormone replacement therapy [topp]
Special [qlco]
Possible [qlco]
Effect [qlco]
Study Design [resa]
OPEN LABEL [resa]
Longitudinal [spco]
Non [ftcn]
Comparative Study [inpr]
Health [idcn]
postmenopausal [tmco]
Women [popg]
treated [topp]
Continuous [idcn]
micronized estradiol [orch, phsu]
mg% [qnco]
Daily [tmco]
Combination [qlco]
Cyclic [tmco]
Dydrogesterone [horm, phsu, strd]
mg% [qnco]
Daily [tmco]
First [qnco]
days [tmco]
treatment [ftcn]
Cycle [tmco]
Women [popg]
Result [ftcn]
serum cholesterol [lbpr]
Low Density Lipoprotein Cholesterol [bacs, strd]
Decreased [qnco]
P NOS [aapp, imft]
High Density Lipoprotein Cholesterol [bacs, lipd]
Increased [qnco]
P NOS [aapp, imft]
Change [ftcn]
Similar [qlco]
increases [ftcn]
Apolipoprotein A-I [aapp, bacs]
P NOS [aapp, imft]
Ii [aapp]
P NOS [aapp, imft]
Apolipoprotein B [aapp, bacs]
Unchanged [fndg]
Serum [bdsu]
Very low density lipoprotein cholesterol [bacs, strd]
very low density lipoprotein triglyceride [aapp, bacs, lipd]
Increased [qnco]
Reflecting [menp]
Slight [qlco]
Increase [ftcn]
serum triglycerides [lbpr]
Values [qlco]
Normal Range [qnco]
Serum [bdsu]
Lipoprotein (a) [aapp, bacs]
Decreased [qnco]
P NOS [aapp, imft]
Calculated [ftcn]
Atherogenesis [patf]
Index [inpr]
Decreased [qnco]
P NOS [aapp, imft]
Study [mnob]
Serum lipids NOS [lbpr]
Lipoproteins [aapp, bacs]
Not [ftcn]
Change [ftcn]
Withdrawal [acty]
Dydrogesterone [horm, phsu, strd]
days [tmco]
Combination Therapy [topp]
Last [qlco]
Cycle [tmco]
Study [mnob]
Serum [bdsu]
Fibrinogen [aapp, bacs, phsu]
Decreased [qnco]
P NOS [aapp, imft]
First [qnco]
Cycle [tmco]
Increased [qnco]
baseline [bodm]
Value [qnco]
P NOS [aapp, imft]
baseline [bodm]
Antithrombin III [aapp, phsu]
Not [ftcn]
Change [ftcn]
Serum Glucose [lbpr]
Decreased [qnco]
Conclusions [idcn]
This [euka]
Hormone replacement therapy [topp]
Regimen [topp]
Induce [ftcn]
GIVEN [cnce]
Long [qlco]
Lipid [lipd]
Profile [lbpr]
Affecting [ftcn]
Indicators [irda]
Thrombosis [patf]
glucose metabolism [moft]
Not [ftcn]
To [qlco]
Interfered [qlco]
Cyclic [tmco]
Administration [ocac]
Dydrogesterone [horm, phsu, strd]
Not [ftcn]
Affect [menp]
Serum lipids NOS [lbpr]
Lipoproteins [aapp, bacs]
Combined [qlco]
Supplementation [topp]
Combination [qlco]
Hormone [horm]
Regimen [topp]
Recommended [idcn]
Hormone replacement therapy [topp]
